{"id":19750,"date":"2024-11-20T12:00:00","date_gmt":"2024-11-20T11:00:00","guid":{"rendered":"https:\/\/inmuno.es\/index.php\/2024\/11\/20\/similar-kinetics-of-pulmonary-sars-cov-2-load-in-intensive-care-unit-patients-with-covid-19-pneumonia-with-or-without-autoantibodies-neutralizing-type-i-interferons\/"},"modified":"2024-11-20T12:00:00","modified_gmt":"2024-11-20T11:00:00","slug":"similar-kinetics-of-pulmonary-sars-cov-2-load-in-intensive-care-unit-patients-with-covid-19-pneumonia-with-or-without-autoantibodies-neutralizing-type-i-interferons","status":"publish","type":"post","link":"https:\/\/inmuno.es\/index.php\/2024\/11\/20\/similar-kinetics-of-pulmonary-sars-cov-2-load-in-intensive-care-unit-patients-with-covid-19-pneumonia-with-or-without-autoantibodies-neutralizing-type-i-interferons\/","title":{"rendered":"Similar Kinetics of Pulmonary SARS-CoV-2 Load in Intensive Care Unit Patients with COVID-19 Pneumonia with or Without Autoantibodies Neutralizing Type I Interferons"},"content":{"rendered":"
\n

J Clin Immunol. 2024 Nov 20;45(1):45. doi: 10.1007\/s10875-024-01839-x.<\/p>\n

ABSTRACT<\/p>\n

PURPOSE: The pathogenesis of life-threatening coronavirus disease 2019 (COVID-19) pneumonia in ICU patients can involve pre-existing auto-antibodies (auto-Abs) neutralizing type I interferons (IFNs). The impact of these auto-Abs on SARS-CoV-2 clearance in the lower respiratory tract (LRT) is unclear.<\/p>\n

METHODS: We performed a retrospective study in 99 ICU patients with COVID-19 pneumonia between March and May 2020. LRT SARS-CoV-2 load (intensity and duration) was analyzed according to the presence or not of circulating auto-Abs neutralizing type I IFNs.<\/p>\n

RESULTS: Among the 99 included patients, 38 (38%) were positive for auto-Abs neutralizing type I IFNs, with 5 (5%) harboring auto-Abs neutralizing IFN-\u03b12 at any concentration, while 33 (33%) had auto-Abs neutralizing only IFN-\u03c9 at the lower concentration. SARS-CoV-2 load in the LRT and duration of viral shedding, were similar in patients with or without auto-Abs neutralizing type I IFNs. Patients with auto-Abs had the same mortality than those without auto-Abs, despite greater occurrence of renal failure and ECMO support, and longer duration of mechanical ventilation and ICU stay.<\/p>\n

CONCLUSION: In summary, 5% of patients with critical COVID-19 pneumonia carried auto-Abs neutralizing IFN-\u03b12, while about 1\/3 harbored auto-Abs neutralizing low concentrations of IFN-\u03c9. The detection of either type of auto-Abs did not impact LRT viral clearance and mortality, although it was associated with greater morbidity and a longer hospitalization. These findings suggest that similar albeit hitherto unknown mechanisms of disease drive critical COVID-19 pneumonia in patients without auto-Abs against type I IFNs.<\/p>\n

PMID:39565497<\/a> | DOI:10.1007\/s10875-024-01839-x<\/a><\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

J Clin Immunol. 2024 Nov 20;45(1):45. doi: 10.1007\/s10875-024-01839-x. ABSTRACT PURPOSE: The pathogenesis of life-threatening coronavirus disease 2019 (COVID-19) pneumonia in ICU patients can involve pre-existing auto-antibodies (auto-Abs) neutralizing type I interferons (IFNs). The impact of these auto-Abs on SARS-CoV-2 clearance in the lower respiratory tract (LRT) is unclear. METHODS: We performed a retrospective study in … Read more<\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[69,42],"tags":[],"class_list":["post-19750","post","type-post","status-publish","format-standard","hentry","category-journal-of-clinical-immunology","category-publicaciones"],"_links":{"self":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/19750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/comments?post=19750"}],"version-history":[{"count":0,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/posts\/19750\/revisions"}],"wp:attachment":[{"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/media?parent=19750"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/categories?post=19750"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/inmuno.es\/index.php\/wp-json\/wp\/v2\/tags?post=19750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}